C9144: Injection, bupivacaine (posimir), 1 mg
C9144 is a HCPCS Level II code for injection, bupivacaine (posimir), 1 mg. It belongs to the Outpatient Prospective Payment System section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
Medically Unlikely Edits: units per day
The most units of C9144 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.
- practitioner
- 660 units MAI 3: Date of Service Edit: Clinical · Prescribing Information
- outpatient
- 660 units MAI 3: Date of Service Edit: Clinical · Prescribing Information
The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute, no documentation overrides it. CMS MUE 2026Q4.
The CMS record for C9144
- Long descriptor
- Injection, bupivacaine (posimir), 1 mg
- Short descriptor
- Inj, bupivacaine (posimir)
- Added
- January 1, 2023
- BETOS
- O1E
- Pricing indicator
- 51: Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Drugs.
Codes adjacent to C9144
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If C9144 is not quite right, the correct code is very often within a few positions of it.
- C9136Injection, factor viii, fc fusion protein, (recombinant), per i.u.terminated
- C9137Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u.terminated
- C9138Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u.terminated
- C9139Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u.terminated
- C9140Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.terminated
- C9141Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.terminated
- C9142Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgterminated
- C9143Cocaine hydrochloride nasal solution (numbrino), 1 mg
- C9145Injection, aprepitant, (aponvie), 1 mgterminated
- C9146Injection, mirvetuximab soravtansine-gynx, 1 mgterminated
- C9147Injection, tremelimumab-actl, 1 mgterminated
- C9148Injection, teclistamab-cqyv, 0.5 mgterminated
- C9149Injection, teplizumab-mzwv, 5 mcgterminated
- C9150Xenon xe-129 hyperpolarized gas, diagnostic, per study doseterminated
- C9151Injection, pegcetacoplan, 1 mgterminated
- C9152Injection, aripiprazole, (abilify asimtufii), 1 mgterminated